ArticleInvestigational new drugs2021

Phase 1 dose escalation study of seribantumab (MM-121), an anti-HER3 monoclonal antibody, in patients with advanced solid tumors.

Crystal S Denlinger et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.